PPARs Signaling and Cancer in the Gastrointestinal System

Valerio Pazienza,1 Manlio Vinciguerra,2 and Gianluigi Mazzoccoli3

1 Gastroenterology Unit IRCCS “Casa Sollievo della Sofferenza” Hospital, Viale dei Cappuccini n.1, 71013 San Giovanni Rotondo, Italy
2 The Institute of Hepatology 69-75 Chenies Mews London, WC1E 6HX London, UK
3 Division of Internal Medicine IRCCS “Casa Sollievo della Sofferenza” Hospital, Viale dei Cappuccini n.1, 71013 San Giovanni Rotondo, Italy

Correspondence should be addressed to Valerio Pazienza, v.pazienza@operapadrepi.it

Received 29 May 2012; Revised 23 July 2012; Accepted 7 August 2012

Academic Editor: Antonio Brunetti

Copyright © 2012 Valerio Pazienza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nowadays, the study of the peroxisome proliferators activated receptors (PPARs) as potential targets for cancer prevention and therapy has gained a strong interest. From a biological point of view, the overall responsibility of PPARs in cancer development and progression is still controversial since several studies report both antiproliferative and tumor-promoting actions for these signaling molecules in human cancer cells and animal models. In this paper, we discuss PPARs functions in the context of different types of gastrointestinal cancer.

1. Introduction

Since the discovery of the peroxisome proliferators activated receptors (PPARs) [1] in Xenopus frogs as receptors that induce the proliferation of peroxisomes in cells [2], three main forms transcribed from three different genes have been identified: PPARα, PPARβ/δ, and PPARγ. Despite the little divergence of homology observed, each isoform possesses distinct biological activities and is expressed in different tissues [3]. PPARα is mainly expressed in the liver, the kidney, and the heart and is primarily involved in lipid metabolism. PPARγ is a master regulator of adipogenesis and fat storage: it regulates adipocyte differentiation and insulin sensitivity in adipose tissue. PPARβ/δ is found in a broad range of tissues but markedly expressed in brain, adipose tissue, and skin and its function awaits further exploration. PPARs are key mediators of energy homeostasis, lipid, and glucose metabolism although they have also been associated with other biological processes including development, differentiation, inflammation, atherosclerosis, wound healing, and tumor formation. All PPARs heterodimerize with the retinoid X receptor (RXR) to bind successively to specific DNA regions of target genes named PPREs (peroxisome proliferator hormone response elements). Like PPARs, RXR exists as three distinct isoforms: RXRα, β, and γ, all of which are activated by the endogenous agonist 9-cis retinoic acid [4]. Contrasting observations confer to PPARs a double-edge sword nature in cancerogenesis, considering that either tumor suppressing or stimulating effects have been evidenced for these nuclear receptors [5].

PPARs function is modified by the specific shape of their ligand-binding domain induced by ligand binding and by a number of coactivator and corepressor proteins, the presence of which can stimulate or inhibit receptor function, respectively [6]. Endogenous ligands for the PPARs include free fatty acids and eicosanoids. PPAR isoform-specific agonists, specifically fibrates for PPARα and thiazolidinediones for PPARγ, are currently prescribed as lipid and glucose-lowering drugs, respectively [7]. Although several reports highlight antiproliferative and prodifferentiative actions of PPARγ ligands in cancer cell lines and animal models of human neoplastic disease [8], more recent studies illustrating tumor-promoting effects of PPARγ, in particular in colon and breast cancer models, raise considerable concern about the practicability and safety of PPARγ ligands as anticancer
addition of 9-
cis
On the other hand, PPAR
ff
ff
ated, and poorly di
components of combination treatments in both in vitro and in vivo models of cancer [11–13]. In particular, a possible role for PPAR as a tumor suppressor and as an inducer of differentiation of cancer stem cells has been explored, and its protein level in tumor specimens has been identified as a significant prognostic marker [14].

A recent meta-analysis has found an association between the PPARG polymorphism 34 C > G and colon cancer risk [15], and a PPAR germline mutation replacing serine 289 with cysteine in the mature protein (S289C) has been reported associated with dyslipidemia and colonic polyp formation progressing to full-blown adenocarcinoma [16]. Furthermore, studies performed in animal models challenged with procarcinogenic and anticarcinogenic agents have put in evidence that PPAR signaling pathway is critically engaged in the antitumor activity of normal organisms [17]. Anyway, the role of PPAR in the neoplastic diseases of the gastrointestinal tract remains controversial, as this nuclear receptor shows dissimilar growth-suppressive effects in different cancers. Moreover, PPAR activation induces diverse growth inhibition in different cancer cell lines [18]. PPAR inhibits tumor growth only in the presence of functional APC but not in cells with loss of APC function [19], and PPAR agonists have been reported to have tumor-promoting effects in the ApcMin/+ mice [10], suggesting that loss of APC may alter the normal response of intestinal epithelial tumor cells to PPAR agonists. The latter could be one important feature that can explain the discrepancies reported in the literature about the dual role of PPAR in gastrointestinal cancer.

In the esophagus, the evaluation of PPAR protein and mRNA expression levels in samples of normal esophageal squamous epithelium, Barrett’s esophagus, and esophageal adenocarcinoma has shown a trend toward increased expression going from normal tissue to pathological samples and a differentiation going from normal tissue to pathological samples and a

2. PPARs and Gastrointestinal Tract Cancer
Numerous studies in the last decade have focused on the effects of PPARs activity on gastrointestinal tract tumor biology, exploring mechanisms, target genes, clinical applications, and evaluating the potential therapeutic use in cancer treatment of PPAR agonists, which seemed promising as components of combination treatments in both in vitro and in vivo models of cancer [11–13]. In particular, a possible role for PPAR as a tumor suppressor and as an inducer of differentiation of cancer stem cells has been explored, and its protein level in tumor specimens has been identified as a significant prognostic marker [14].

Regarding the large bowel, high expression of PPARy is detected in the normal mucosa of the colon and rectum, and a deficiency in intestinal PPARy is associated with enhanced tumorigenicity in mouse small intestine and colon. A series of evidence suggests that PPAR is a tumor suppressor gene in colorectal cancer: (i) loss of function point mutations has been evidenced in one allele of PPAR in primary colorectal patients, and the mutations impair the function of PPAR by affecting the ligand-binding domain, which results in an inability to bind ligands and control gene regulation; (ii) polymorphism in the PPARy gene has been found in colorectal cancer patients; (iii) expression of PPARy in colorectal cancer is associated with a good prognosis [24]. Anyway, decreased PPARy expression compared with adjacent normal colonic mucosa is detected in a number of colorectal cancer patients [25], and PPAR inactivation seems to play a role in colorectal cancer progression, although the events involved are not yet clear. In a large series of primary colorectal cancers, about 60% of tumors showed PPAR upregulation, whereas 35% of the tumours showed lower PPARy levels compared to the nontumorous normal mucosa. A significant association was evidenced between low PPARy expression and distant metastases and reduced patients’ survival [26].

PPARG epigenetic silencing has been found to be coordinated by ubiquitin-like with PHD and RING finger domains 1 (UHRF1), a member of a subfamily of RING-finger-type E3 ubiquitin ligases, which mediates colorectal cancer progression. This protein is encoded by the UHRF1 gene and its expression peaks at late G1 phase and continues during G2 and M phases of the cell cycle, playing a major role in the G1/S transition by regulating topoisomerase II alpha and retinoblastoma gene expression and functioning in the p53-dependent DNA damage checkpoints. UHRF1 binds to specific DNA sequences and recruits a histone deacetylase to regulate gene expression, functioning as a cofactor that coordinates the epigenetic silencing of tumor suppressor genes. UHRF1 overexpression induces PPARG silencing through its recruitment on the PPARG promoter promoting DNA methylation and histone repressive modifications, and it is associated with a higher proliferative, clonogenic, and migration potential, and with phenotypic features resembling those occurring in the epithelial-mesenchymal transition [27]. PPARy agonists such as thiazolidinediones, also known as glitazones (rosiglitazone, troglitazone, and pioglitazone), have been shown to induce apoptosis in human colon cancer cells, and the molecular mechanism involves glycogen synthase kinase-3β (GSK-3β), a crucial activator of nuclear factor-kappa B (NF-kappaB), which plays a critical role in the mediation of survival signals in cancer cells, with inhibition of NF-kappaB activity and GSK-3β expression in a dose-dependent manner. Glitazone treatment inhibits colon cancer cell growth, and cells are arrested in G(0)/G(1) phase followed by the induction of apoptosis with concomitant
decrease in the expression of the G(0)/G(1) phase regulatory proteins Cdk2, Cdk4, cyclin B1, D1, and E, decrease in the antiapoptotic protein Bcl-2, and increase in the expression of the proapoaptotic proteins caspase-3, caspase-9, and Bax [28]. Similarly to the phenomenon evidenced in gastric cancer lines [23], the effect is augmented by the simultaneous addition of the RXRα ligand 9-cis retinoic acid [29].

On the other hand, inhibiting PPARy prevents proliferation of human colon cancer HT-29 cells, as evidenced by challenge with cyclic phosphatidic acid (cPA), a structural analog of lysophosphatidic acid (LPA), and a specific, high-affinity PPARy antagonist [30]. Moreover, synthetic and physiological agonists of PPARy and PPARβ/δ induce expression of vascular endothelial growth factor (VEGF) in the colorectal tumor cell lines SW480 and HT29 [31]. Interestingly, PPARβ/δ is a promising drug target since its agonists promote terminal differentiation, but there are reports showing either pro- or anticarcinogenic effects of PPARβ/δ in cancer models [32]. Expression of PPARβ/δ mRNA and protein is lower in human and Apc (+/−Min-FCCC) mouse colon tumors in respect of matched normal tissue, and stable overexpression of PPARβ/δ in human HT29 colon cancer cell lines enhances ligand activation of PPARβ/δ and inhibition of clonogenicity [33]. The role of PPARβ/δ in the pathogenesis of colorectal cancer has been evaluated in studies performed in vivo on rectal cancer patients and in vitro on colon cancer cell lines with different metastatic potentials. The intensity of PPARβ/δ expression has been found increased in human rectal cancer tissue compared to adjacent or distant normal mucosa [34], in rectal cancers with better differentiation than in those with poor differentiation, and in early-stage tumors than in advanced ones [35]. Besides, PPARβ knockdown in vitro has evidenced that PPARβ/δ may facilitate differentiation and inhibit the cell-fibronectin adhesion of colon cancer cell lines [35].

Anyway, some colorectal cancer cell lines are resistant to PPARy agonists, because elevated PPARy expression and/or activation of PPARδ antagonize the ability of PPARy to induce colorectal carcinoma cell death, as a result of opposing effects of PPARδ and PPARy in regulating programmed cell death mediated by survivin and caspase-3: activation of PPARy results in decreased survivin expression and increased caspase-3 activity, whereas activation of PPARδ counteracts these effects [36]. In addition, the concomitant expression of PPAR β/δ and cyclooxygenase (COX)-2 in tumor tissues is associated with a higher incidence of liver metastasis and consequent poor prognosis in colorectal cancer patients [37].

PPARy activation induces expression of Krüppel-like factor (KLF) 4, known also as gut-enriched Krüppel-like factor (GKLF), which acts as a transcriptional activator or repressor depending on the promoter context and/or cooperation with other transcription factors. KLF4 is a nodal player in the network of PPARγ-regulated genes, and treatment of colon cancer cells with PPARγ agonists influences KLF4 target genes, whose expression is decreased (cyclin D1) or increased (GPA33, encoding the glycoprotein A33 that is a colon cancer antigen, p21WAF1/Cip1, and keratin 19), respectively [38].

Epigentic silencing of PPARγ in colorectal cancer may be a significant prognostic marker of tumor progression, and methylation on a specific region of the promoter is strongly correlated with PPARγ lack of expression in primary colorectal cancers and with patients’ poor prognosis [26]. The same methylation pattern is found in PPARγ negative colorectal cancer cell lines. Transcriptional silencing is due to the recruitment of methyl CpG binding protein 2 (MeCP2), histone deacetylase 1 (HDAC1), and histone-lysine N-methyltransferase (EZH2) that impart repressive chromatin signatures determining an increased cell proliferative and invasive potential [26].

As reported in this section, many clinical and experimental data support the critical role played by PPARs in gastrointestinal tumorigenesis and neoplastic gut disease behavior, but the molecular mechanisms involved are still a matter of debate. Furthermore, the results of many studies are conflicting and lead to the conclusion that PPARs may have both tumor suppressor and procarcinogenic activity. These controversies may arise from methodological differences among the study protocols, anyway some evidence suggests that ligand-related PPARs activation induces growth arrest in cancer cells and tumor growth inhibition deriving from antiproliferative or proapoptotic effects. On the other hand, PPARs have been found to stimulate tumor cell proliferation and induce neo-angiogenesis, favoring cancer growth and spreading. PPARs agonists provoke several physiological modifications influencing lipid metabolism, glucose homeostasis, and inflammation signaling cascade, and considering that among the major risk factors for colorectal cancer are comprised obesity, metabolic derangement, and chronic inflammatory bowel disease, PPARs modulation could be a valuable tool in the prevention and treatment of colorectal cancer. A mandatory and preliminary condition is represented by the full understanding of the complex mechanisms involved in the regulation of PPARs transcriptional activity and unveiling of the intricacy of PPAR-dependent and PPAR-independent effects stimulated by the different ligands. The same PPAR is able to modulate different target genes and cooperate with other nuclear receptors and signalling molecules involved in cell proliferation and cell death, increasing the difficulty to dissect the role of the single players that take part in this physiologically basic but really intricate network.

3. PPARs and Liver Cancer

Hepatocellular carcinoma (HCC) is the most common type of liver cancer. HCC often arises from viral hepatitis infection (hepatitis B or C), cirrhosis, alcohol consumption being its most common cause. HCC has recently been linked to nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of obesity and metabolic syndrome. HCC presents with an aberrant lipid metabolism as revealed by quantitative profiling in patient plasma by using ultraperformance liquid chromatography coupled to mass spectrometry approaches.
HepG2 cells in a dose-dependent manner [57]. Moreover, it was shown that PPAR in the partial hepatectomy rat model of liver regeneration, PPAR\(\gamma\) inhibits growth through reducing cell proliferation and inducing \(\alpha\) inhibition of liver growth during regeneration [58]. PPARs of the cycle [55]. Mice lacking one allele of \(\alpha\) hepatocarcinoma cells, PPAR\(\alpha\) is chiefly related to apoptosis as evidenced by determination of BAD, myc, and protein phosphatase 2A protein content and PPAR\(\gamma\) is instead chiefly suppressed tumor cell differentiation factor-15 [56]. Consistently, troglitazone, a PPAR\(\gamma\) ligand, inhibited growth and induced apoptosis of HepG2 cells in a dose-dependent manner [57]. Moreover, in the partial hepatectomy rat model of liver regeneration, it was shown that PPAR\(\gamma\) signaling is a key negative regulator of hepatocyte proliferation and may be responsible for the inhibition of liver growth during regeneration [58]. PPARs actively crosstalk with other signaling mediators implicated in lipid metabolism and hepatocyte malignancy; for instance, AMP-activated protein kinase (AMPK), an energy sensing enzyme implicated in the transition from NAFLD to HCC [59], and whose activation has been reported to be lipid lowering and antitumoral in mice and in hepatoma cells [60, 61]. In HCC cells, AMPK activators AICAR and metformin inhibit directly transcriptional activities of PPAR\(\alpha\) and PPAR\(\gamma\) to modulate energy generation through fatty acid oxidation process [62]. Mice with a combination of genetic inactivations for hepatic growth hormone and glucocorticoid receptor signaling effectors displayed upregulation of proapoptotic PPAR\(\gamma\) and downstream transcription factor SREBP-1c, demonstrating a crosstalk between these molecular networks [63]. Mice with specific inactivation of the NF-kappaB essential modulator gene (NEMO (L-KO) mice) exposed to a high-fat diet display a worsened liver steatosis as a consequence of PPAR\(\alpha\) and increased PPAR\(\gamma\) expression [64]. From a therapeutic perspective, PPAR\(\gamma\) agonists, such as antidiabetic thiazolidinediones (TZD), have in vitro antiproliferative effect, have been associated with lower risk and a better prognosis in HCC, not only related to anti-NAFLD but also to antiviral hepatitis effects [65]. The effective anticancer properties and the underlying molecular mechanisms of these drugs in vivo remain unclear because the primary target of TZD is PPAR\(\gamma\), which is upregulated in HCC and seems to provide tumor-promoting responses. Reconciling this discrepancy, it may be that these established PPARs agonists exert a hypolipidemic and antitumoral action in liver cells through PPAR-independent pathways [66, 67].

As mentioned, when the liver is infected with hepatic viruses, this can ultimately result in liver cancer, and hepatitis viruses are one of the leading causes of chronic liver disease [68]. Hepatitis viruses are a global health problem if we consider approximately 200 million patients carrying a chronic HCV infection and about 350 million chronically infected with HBV [69].

PPARs were suggested as new therapeutic targets in the traditional treatment of HCV-induced liver injury when two studies found that PPARs drastically decreased in HCV-infected patients [70] together with its target gene carnitine palmitoyl acyl-CoA transferase 1A (CPT1A) [71]. The impaired PPAR\(\gamma\) expression was due to HCV core protein expression [71]. Successively, we and others have recently uncovered a role for PPAR\(\gamma\) in HCV infection [42, 72, 73]. Granted that HCV is classified in six different major genotypes and that mechanisms involved in pathobiology of disease are genotype dependent [39, 73], from a biological point of view, reduced PPAR\(\gamma\) levels found in in vitro models of HCV expressing the core protein genotype 3a are associated with increased fat accumulation and impaired insulin signaling [72, 73]. The latter impairs the sustained response rate to peg-interferon plus ribavirin in chronic hepatitis C patients [40]. PPAR\(\gamma\) degrades IRS1 protein through suppressor of cytokine signaling protein 7 (SOCS-7) whose expression could be pharmacologically controlled by agonist and antagonist of PPAR\(\gamma\) [41]. PPAR\(\gamma\) agonists have already been suggested as an adjuvant therapy in chronic hepatitis C [74, 75]. In fact, there is the belief that correcting insulin resistance is a rational option in chronic hepatitis C patients [76]. However, new modalities of this correction have to be explored based on the mechanisms inducing insulin resistance, as insulin-sensitizing therapy...
should be tailored according to the infecting HCV genotype, as suggested [76].

Steatosis is a common histological feature of chronic infection between hepatitis C and B virus. Another common feature is the ability of both viruses in modulating PPARα and PPARγ activity/expression which are related to steatosis. As for HBV, in vitro studies using hepatoma cell lines and studies on transgenic mouse models for HBV have provided indication for a role of PPARs in HBV-related diseases and in controlling viral transcription and replication. Kim et al. [77] demonstrated that SREBP-1 and PPARγ were transcriptionally induced by HBV X protein (HBx) in order to provoke hepatic steatosis in HepG2-HBx stable cells and HBx-transgenic mice.

Moreover thiazolidinediones (TZD, class of PPARγ ligands) have been suggested as useful drugs for HCC chemoprevention and treatment as TZD administration in hepatitis B virus (HBV)-transgenic mice reduced tumor incidence in the liver, inhibiting hepatocyte proliferation and increasing apoptosis, probably through inhibition of nuclearephosmin (NPM) protein and mRNA expression [68]. Furthermore it was also reported a role for PPARs in regulating HBV transcription and regulation in vivo [78] and in vitro [79]. Guidotti et al. [78] demonstrated that HBV transgenic mice treated with two synthetic PPARα ligands (Wy-14,643 and clofibric acid) resulted in an increased HBV transcription rates suggesting that in patients receiving these drugs who are also infected with HBV viral replication may be activated, and this could have potentially detrimental effects on the outcome of the viral infection. Conversely, Waku et al. [79] demonstrated that the PPARα ligand bezafibrate had no effect on HBV replication within HepG2 cells whilst a PPARγ ligand, rosiglitazone, reduced the amount of HBV DNA, hepatitis B surface antigen (HBsAg), and hepatitis B e antigen (HBeAg) in the culture supernatant, suggesting that the combination therapy of rosiglitazone and nucleot(s)ide analogues or interferon could be a therapeutic rational option also for chronic HBV infection.

4. PPARs and Pancreatic Cancer

Pancreatic cancer (PC) is one of the most lethal malignant diseases with a really terrible prognosis and is ranked as the fourth leading cause of cancer-related deaths worldwide [80]. PC is referred to as a “silent killer” because early pancreatic cancer often does not cause symptoms and the later symptoms are usually nonspecific and varied. Despite many advances in modern medicine, the available therapeutic strategies based on surgery and conventional chemotherapy are still largely unsatisfactory in patients with pancreatic cancer. When patients present locally advanced or metastatic tumors (which render them ineligible for surgical resection), they are treated with the gold standard chemotherapy which is based on gemcitabine, an S-phase nucleoside cytidine analogue. The overall survival is unacceptably small, and novel therapeutic approaches to overcome the resistance of PC to conventional anticancer therapies are urgently needed. Scientists are also looking for an ideal combination partner in therapeutic settings that require the inhibition of tumor-protecting mechanisms/proteins to overcome treatment resistance.

PPARγ is commonly upregulated in pancreatic ductal adenocarcinoma and might be considered a prognostic marker in this disease [81].

To date several research groups have demonstrated the ability of thiazolidinedione (TZD, class of PPARγ ligands) to attenuate the growth of pancreatic cancer cells in vitro, which was associated to G1 cell cycle arrest and cell differentiation and to increased apoptotic cell death [43]. Moreover, Hashimoto et al. [82] suggest a double beneficial effect of TZD showing the dual advantage of inhibiting pancreatic cancer cell growth while reducing the invasiveness of the tumor cells. Moreover, TZD attenuated pancreatic cancer cell migration and invasion by modulation of actin organization and expression of matrix metalloproteinase-2 and plasminogen activator inhibitor-1, respectively [83, 84]. An increasing number of studies have implicated STAT activation, particularly STAT3, in transformation and tumor progression. Direct targeting of STAT3 in malignant tumors may represent another important therapeutic tool as STAT proteins are emerging as ideal targets for cancer therapy [44]. Vitale et al. [85] showed that, in pancreatic cancer cells, PPAR-γ agonist (troglitazone, TGZ) counteracts STAT3 protein potentiating the anticancer effects of IFN-β through the induction of cell cycle perturbations and the occurrence of autophagy cell death in pancreatic cancer cells. Co-incubation of pancreatic cancer cells with IFN-β and TGZ suppresses STAT3 activation and delays G0/G1-S phase progression that occurred together with an increase in p21 and p27 protein expression that was more evident after 24 hours of treatment with the pharmacological combination.

Even though we did not observe a PPARγ altered expression in 30 matched pairs of tumour and adjacent normal tissue samples collected from patients undergoing pancreatic resection [45], a recent study supports a role of PPARγ as an ideal partner of the standard therapy based on gemcitabine since the anticancer effect of gemcitabine can be enhanced by ligands for PPARγ such as pioglitazone (Pio) and rosiglitazone [86]. The authors demonstrate that Pio significantly inhibits the NF-κB transcriptional activity and potentiates the gemcitabine effect on the apoptosis rate in three different pancreatic cancer cell lines as demonstrated by cotreatment with Pio and Gem on caspase-3 and caspase-7 cleavage. The authors conclude that since Pio is widely used in the treatment of diabetes mellitus, it may become a possible partner of Gem-based chemotherapy. Considered the adverse effects associated with TZDs, such as weight gain, macular edema, bone loss, and heart failure in at-risk individuals [87, 88], scientists must press on investigating new analogs of PPARγ agonists in order to potentiate the beneficial effect while reducing the side effects (Figure 1 and Table 1).

5. Conclusion

A potential role for PPARs agonists in the adjuvant treatment of digestive system cancers is advisable, but further studies...
Table 1: Differential patterns of PPARs expression in gastrointestinal system disease.

| Organ        | PPARs expression | Author and reference |
|--------------|------------------|----------------------|
| Esophagus    | PPARγ↑           | Wang et al. [20]     |
|              | PPARγ↑           |                      |
| Stomach      | PPARγ↑           | Ma et al. [21]       |
|              | PPARγ↑           | Yao et al. [22]      |
|              | PPARγ↑           | Sato et al. [23]     |
| Colon-rectum | PPARγ↓           | Dai and Wang [24]    |
|              | PPARγ↓           | Pancione et al. [26] |
| Liver        | PPARα and PPARγ↓ | Ripoli and Pazienza [39] |
|              | PPARγ↑           | Romero-Gómez et al. [40] |
|              | PPARγ↑           | Pazienza et al. [41] |
|              | PPARγ↑           | Dharancy et al. [42] |
|              | PPARγ↑           | Tsujie et al. [43]   |
| Pancreas     | PPARγ↑           | Yu and Jove [44]     |
|              | PPARγ—           | Pazienza et al. [45] |

**Figure 1:** Schematic representation of the PPARs signaling operating in cancer. Krueppel-like factor 4 (KLF4); cyclin-dependent kinase (2, 4); cyclin B1, D1; ubiquitin-like, containing PHD and RING finger domains, 1; methyl CpG binding protein 2 (MeCP2); Histone deacetylase 1 (HDAC1); histone-lysine N-methyltransferase (EZH2); matrix metalloproteinase 2 (MMP2); plasminogen activator inhibitor 1 (PAI-1) nuclear factor-kappaB (NFκB); nucleophosmin (NPM); insulin receptor substrate 1 (IRS-1); suppressor of cytokine signal (SOCS). For further explanations, please refer to the text.
are warranted in order to better clarify the role of PPARs in gastrointestinal cancerogenesis. PPARs could have prognostic and/or therapeutic roles, but there is urgent need to shed light on the favorable potential or harmful risk of their modulators.

Conflict of Interests
The authors declare that they have no competing interests.

Acknowledgments
This work was supported by “Ministry of Italian Health” Grant through the Research Laboratory and Gastroenterology Unit (RC1203GA58) and Division of Internal Medicine and Chronobiology Unit (RC1203ME46), IRCCS Scientific Institute and Regional General Hospital “Casa Sollievo della Sofferenza,” Opera di Padre Pio da Pietrelcina, San Giovanni Rotondo, Italy, and by the “5x1000” voluntary contributions.

References
[1] I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” *Nature*, vol. 347, no. 6294, pp. 645–650, 1990.
[2] C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W. Wahl, “Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors,” *Cell*, vol. 68, no. 5, pp. 879–887, 1992.
[3] P. Escher and W. Wahl, “Peroxisome proliferator-activated receptors: Insight into multiple cellular functions,” *Mutation Research*, vol. 448, no. 2, pp. 121–138, 2000.
[4] D. J. Mangelsdorf, U. Bögner, R. A. Heyman et al., “Characterization of three RXR genes that mediate the action of 9-cis retinoic acid,” *Genes and Development*, vol. 6, no. 3, pp. 329–344, 1992.
[5] D. Panigrahy, A. Kaipainen, M. W. Kieran, and S. Huang, “PPARs: a double-edged sword in cancer therapy?” *PPAR Research*, vol. 2008, Article ID 350351, 2 pages, 2008.
[6] S. Yu and J. K. Reddy, “Transcription coactivators for peroxisome proliferator-activated receptors,” *Biochimica et Biophysica Acta*, vol. 1771, no. 8, pp. 936–951, 2007.
[7] W. Xu and P. Charoenaksook, “PPARs in rhytmic metabolic regulation and implications in health and disease,” *PPAR Research*, vol. 2010, Article ID 243643, 9 pages, 2010.
[8] G. Eibl, “The role of PPAR-γ and its interaction with COX-2 in pancreatic cancer,” *PPAR Research*, vol. 2008, Article ID 326915, 6 pages, 2008.
[9] K. Yang, K. H. Fan, S. A. Lamprecht et al., “Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6 mice and enhances colonic carcinogenesis in Apc1638N/+ Mlh1+/- double mutant mice,” *International Journal of Cancer*, vol. 116, no. 4, pp. 495–499, 2005.
[10] M. V. Pino, M. F. Kelley, and Z. Jayyosi, “Promotion of colon tumors in C57BL/6J-APCmin/+ mice by thiazolidinedione PPARγ agonists and a structurally unrelated PPARγ agonist,” *Toxicologic Pathology*, vol. 32, no. 1, pp. 58–63, 2004.
[11] I. A. Voutsadakis, “Peroxisome proliferator-activated receptor γ (PPARγ) and colorectal carcinogenesis,” *Journal of Cancer Research and Clinical Oncology*, vol. 133, no. 12, pp. 917–928, 2007.
[12] J. Bassaganya-Riera, A. B. Carter, S. A. Misyak, and R. Hontecillas, “Dietary modulation of inflammation-induced colorectal cancer through PPARγ,” *PPAR Research*, vol. 2009, Article ID 498352, 9 pages, 2009.
[13] J. M. Peters, Y. M. Shah, and F. J. Gonzalez, “The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention,” *Nature Reviews Cancer*, vol. 12, no. 3, pp. 181–195, 2012.
[14] G. T. Robbins and D. Nie, “PPAR gamma, bioactive lipids, and cancer progression,” *Frontiers in Bioscience*, vol. 17, pp. 1816–1834, 2012.
[15] Y. L. Lu, G. L. Li, H. L. Huang, J. Zhong, and L. C. Dai, “Peroxisome proliferator-activated receptor-γ 34C>G polymorphism and colorectal cancer risk: a meta-analysis,” *World Journal of Gastroenterology*, vol. 16, no. 17, pp. 2170–2175, 2010.
[16] D. Capaccio, A. Ciccodicola, L. Sabatino et al., “A novel germ-line mutation in peroxisome proliferator-activated receptor γ gene associated with large intestine polyp formation and dyslipidemia,” *Biochimica et Biophysica Acta*, vol. 1802, no. 6, pp. 572–581, 2010.
[17] Y. Dai, L. Qiao, W. C. Kwok et al., “Peroxisome proliferator-activated receptor-γ contributes to the inhibitory effects of embelin on colon carcinogenesis,” *Cancer Research*, vol. 69, no. 11, pp. 4776–4783, 2009.
[18] L. Qiao, B. Zou, and B. C. Y. Wong, “Current understanding of the role of PPAR γ in gastrointestinal cancers,” *PPAR Research*, vol. 2009, Article ID 816957, 8 pages, 2009.
[19] G. D. Girmun, W. M. Smith, S. Drott et al., “APC-dependent suppression of colon carcinogenesis by PPARγ,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 21, pp. 13771–13776, 2002.
[20] W. Wang, R. Wang, Z. Zhang, D. Li, and Y. Yu, “Enhanced PPAR-γ expression may correlate with the development of Barrett’s esophagus and esophageal adenocarcinoma,” *Oncology Research*, vol. 19, no. 3–4, pp. 141–147, 2011.
[21] X. M. Ma, H. Yu, and N. Huai, “Peroxisome proliferator-activated receptor-γ is essential in the pathogenesis of gastric carcinoma,” *World Journal of Gastroenterology*, vol. 15, no. 31, pp. 3874–3883, 2009.
[22] L. Yao, F. Liu, L. Sun et al., “Upregulation of PPARγ in tissue with gastric carcinoma,” *Hybridoma*, vol. 29, no. 4, pp. 341–343, 2010.
[23] H. Sato, S. Ishihara, K. Kawashima et al., “Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists,” *British Journal of Cancer*, vol. 83, no. 10, pp. 1394–1400, 2000.
[24] Y. Dai and W. H. Wang, “Peroxisome proliferator-activated receptor γ and colorectal cancer,” *The World Journal of Gastrointestinal Oncology*, vol. 2, no. 3, pp. 159–164, 2010.
[25] P. A. Konstantinopoulos, G. P. Vardanos, G. Sotropoulou-Bonikou, A. Kominea, and A. G. Papavassiliou, “NF-κB/PPARγ and/or AP-1/PPARγ ‘on/off’ switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression,” *International Journal of Colorectal Disease*, vol. 22, no. 1, pp. 57–68, 2007.
[26] M. Pancione, L. Sabatino, A. Fucci et al., “Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients’ outcome,” *PLoS One*, vol. 5, no. 12, Article ID e14229, 2010.
[27] L. Sabatino, A. Fucci, M. Pancione et al., “UHRF1 coordinates peroxisome proliferator activated receptor gamma (PPARG)
epigenetic silencing and mediates colorectal cancer progression," Oncogene. In press.

[28] J. O. Ban, D. H. Kwak, J. H. Oh et al., "Suppression of NF-κB and GSK-3β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone," Chemico-Biological Interactions, vol. 188, no. 1, pp. 75–85, 2010.

[29] A. Papi, P. Rocchi, A. M. Ferreri, and M. Orlandi, "RXRγ and PPARγ ligands in combination to inhibit proliferation and invasiveness in colon cancer cells," Cancer Letters, vol. 297, no. 1, pp. 65–74, 2010.

[30] T. Tsukahara, S. Hanazawa, T. Kobayashi, Y. Iwamoto, and J. O. Ban, D. H. Kwak, J. H. Oh et al., "Suppression of NF-κB and GSK-3β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone," Chemico-Biological Interactions, vol. 188, no. 1, pp. 75–85, 2010.

[31] C. Röhrl, U. Kaindl, I. Koneczny et al., "Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells," Journal of Cancer Research and Clinical Oncology, vol. 137, no. 1, pp. 29–39, 2011.

[32] J. M. Peters, J. E. Foreman, and F. J. Gonzalez, "Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis," Cancer and Metastasis Reviews, vol. 30, no. 3–4, pp. 619–640, 2011.

[33] J. E. Foreman, W. C. L. Chang, P. S. Palkar et al., "Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer," Molecular Carcinogenesis, vol. 50, no. 11, pp. 884–900, 2011.

[34] L. Yang, H. Zhang, Z. G. Zhou, H. Yan, G. Adell, and X. F. Sun, "Biological function and prognostic significance of peroxisome proliferator-activated receptor δ in rectal cancer," Clinical Cancer Research, vol. 17, no. 11, pp. 3760–3770, 2011.

[35] L. Yang, B. Olsson, D. Pfeifer et al., "Knockdown of peroxisome proliferator-activated receptor-β/δ induces less differentiation and enhances cell-fibronectin adhesion of colon cancer cells," Oncogene, vol. 29, no. 4, pp. 516–526, 2010.

[36] D. Wang, W. Ning, D. Xie, L. Guo, and R. N. DuBois, "Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells," Oncogene, vol. 31, no. 8, pp. 1013–1023, 2012.

[37] M. Yoshinaga, K. Taki, S. Somada et al., "The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients," Digestive Diseases and Sciences, vol. 56, no. 4, pp. 1194–1200, 2011.

[38] J. Rageul, S. Mottier, A. Jarry et al., "KLF4-dependent, PPARγ-driven expression of GPA33 in colon cancer cell lines," International Journal of Cancer, vol. 125, no. 12, pp. 2802–2809, 2009.

[39] M. Ripoli and V. Pazienza, "Impact of HCV genetic differences on pathobiology of disease," Expert Review of Anti-Infective Therapy, vol. 9, no. 9, pp. 747–759, 2011.

[40] M. Romero-Gómez, M. Del Mar Viloria, R. J. Andrade et al., "Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients," Gastroenterology, vol. 128, no. 3, pp. 636–641, 2005.

[41] V. Pazienza, M. Vinciguerra, A. Andriulli, and A. Mangia, "Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-γ in Huh-7 cells," Journal of General Virology, vol. 91, no. 7, pp. 1678–1686, 2010.

[42] S. Dharancy, M. Lemoine, P. Mathurin, L. Serfaty, and L. Dubuquoy, "Peroxisome proliferator-activated receptors in HCV-related infection," PPAR Research, vol. 2009, Article ID 357204, 5 pages, 2009.

[43] M. Tsuie, S. Nakamori, J. Okami et al., "Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retnoid X receptor alpha pathway," Experimental Cell Research, vol. 289, no. 1, pp. 143–151, 2003.

[44] H. Yu and R. Jove, "The stats of cancer—new molecular targets come of age," Nature Reviews Cancer, vol. 4, no. 2, pp. 97–105, 2004.

[45] V. Pazienza, F. Tavano, G. Benegiamo et al., "Correlations among PPARα, DNMT1, and DNMT3B expression levels and pancreatic cancer," PPAR Research, vol. 2012, Article ID 461784, 7 pages, 2012.

[46] A. D. Patterson, O. Maurhofer, D. Beygou et al., "Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling," Cancer Research, vol. 71, no. 21, pp. 6590–6600, 2011.

[47] M. Vaccara, C. Delegirolamo, R. Mariani-Costantini, G. Palasciano, and A. Moschetta, "Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome," Wiley Interdisciplinary Reviews: Systems Biology and Medicine, vol. 3, no. 5, pp. 562–587, 2011.

[48] G. Li and G. L. Guo, "Role of class II nuclear receptors in liver carcinogenesis," Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 6, pp. 529–542, 2011.

[49] K. Matsusue, T. Kusakabe, T. Neguchi et al., "Hepatic steatosis in leptin-deficient mice is promoted by the PPARγ target gene Fsp27," Cell Metabolism, vol. 7, no. 4, pp. 302–311, 2008.

[50] D. L. van der Meer, T. Degenhardt, S. Väisänen et al., "Profiling of promoter occupancy by PPARα in human hepatoma cells via ChIP-chip analysis," Nucleic Acids Research, vol. 38, no. 9, Article ID gkq012, pp. 2839–2850, 2010.

[51] K. Z. Guyton, W. A. Chiu, T. F. Bateson et al., "A reexamination of the PPAR-α activation mode of action as a basis for assessing human cancer risks of environmental contaminants," Environmental Health Perspectives, vol. 117, no. 11, pp. 1664–1672, 2009.

[52] J. C. Corton, "Evaluation of the role of peroxisome proliferator-activated receptor α (PPARα) in mouse liver tumor induction by trichloroethylene and metabolites," Critical Reviews in Toxicology, vol. 38, no. 10, pp. 857–875, 2008.

[53] N. Tanaka, K. Moriya, K. Kiyosawa, K. Koike, and T. Aoyama, "PPARα activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice," Journal of Clinical Investigation, vol. 118, no. 2, pp. 683–694, 2008.

[54] N. Tanaka, K. Moriya, K. Kiyosawa, K. Koike, and T. Aoyama, "Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferator-activated receptor α in transgenic mice: Implications for HCV-associated hepatocarcinogenesis," International Journal of Cancer, vol. 122, no. 1, pp. 124–131, 2008.

[55] M. Maggiora, M. Oraldi, G. Muzio, and R. A. Canuto, "Involvement of PPARα and PPARγ in apoptosis and proliferation of human hepatocarcinoma HepG2 cells," Cell Biochemistry and Function, vol. 28, no. 7, pp. 571–577, 2010.

[56] J. Yu, B. Shen, E. S. H. Chu, C. L. Radomski, W. S. Inglese, and W. H. Lee, "Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro," Hepatology, vol. 51, no. 6, pp. 2008–2019, 2010.
Y. M. Zhou, Y. H. Wen, X. Y. Kang, H. H. Qian, J. M. Yang, and Z. F. Yin, “Troglitazone, a peroxisome proliferator-activated receptor γ ligand, induces growth inhibition and apoptosis of HepG2 human liver cancer cells,” World Journal of Gastroenterology, vol. 14, no. 14, pp. 2168–2173, 2008.

Y. Yamamoto, T. Ono, D. K. Dhar et al., “Role of peroxisome proliferator-activated receptor-gamma (PPARγ) during liver regeneration in rats,” Journal of Gastroenterology and Hepatology, vol. 23, no. 6, pp. 930–937, 2008.

N. Martínez-López, M. Varela-Rey, D. Fernández-Ramos et al., “Activation of LKB1-Akt pathway independent of phosphoinositide 3-kinase plays a critical role in the proliferation of hepatocellular carcinoma from nonalcoholic steatohepatitis,” Hepatology, vol. 52, no. 5, pp. 1621–1631, 2010.

D. Vara, M. Salazar, N. Olea-Herrero, M. Guzmán, G. Velasco, and J. Díaz-Laviada, “Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy,” Cell Death and Differentiation, vol. 18, no. 7, pp. 1099–1111, 2011.

K. Bhalla, B. J. Hwang, R. E. Dewi et al., “Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis,” Cancer Prevention Research, vol. 5, no. 4, pp. 544–552, 2012.

M. S. Sozio, C. Lu, Y. Zeng, S. Liangpunsakul, and D. W. Crabb, “Activated AMPK inhibits PPAR-α and PPARγ transcriptional activity in hepatic cells,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 301, no. 4, pp. G739–G747, 2011.

K. M. Mueller, J. W. Kornfeld, K. Friedbichler et al., “Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice,” Hepatology, vol. 54, no. 4, pp. 1398–1409, 2011.

F. T. Wunderlich, T. Luedde, S. Singer et al., “Hepatic NF-kB essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 4, pp. 1297–1302, 2008.

J. Shim, B. H. Kim, Y. I. Kim et al., “The peroxisome proliferator-activated receptor γ ligands, pioglitazone and 15-deoxy-D12,14-prostaglandin J2, have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells,” International Journal of Oncology, vol. 36, no. 1, pp. 223–231, 2010.

D. Yamasaki, N. Kawabe, H. Nakamura et al., “Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms,” European Journal of Cell Biology, vol. 90, no. 8, pp. 657–664, 2011.

A. Galli, E. Ceni, T. Mello et al., “Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor γ-independent regulation of nuclearephin,” Hepatology, vol. 52, no. 2, pp. 493–505, 2010.

I. Saito, T. Miyamura, A. Ohbayashi et al., “Hepatitis C virus infection is associated with the development of hepatocellular carcinoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 17, pp. 6547–6549, 1990.

S. Dharancy, M. Lemoine, P. Mathurin, L. Serfaty, and L. Dubuquoy, “Peroxisome proliferator-activated receptors in HCV-related infection,” PPAR Research, vol. 2009, Article ID 57204, 5 pages, 2009.

Y. Cheng, S. Dharancy, M. Malapel, and P. Desreumaux, “Hepatitis C virus infection down-regulates the expression of peroxisome proliferator-activated receptor α and carnitine palmitoyl acyl-CoA transferase 1A,” World Journal of Gastroenterology, vol. 11, no. 48, pp. 7591–7596, 2005.

S. Dharancy, M. Malapel, G. Perlemuter et al., “Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection,” Gastroenterology, vol. 128, no. 2, pp. 334–342, 2005.

A. De Gottardi, V. Pazienza, P. Pugnale et al., “Peroxisome proliferator-activated receptor-α and -γ mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection,” Alimentary Pharmacology and Therapeutics, vol. 23, no. 1, pp. 107–114, 2006.

V. Pazienza, S. Clément, P. Pugnale et al., “The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms,” Hepatology, vol. 45, no. 5, pp. 1164–1171, 2007.

H. M. Elgoughari, K. B. Cesario, R. Lopez, and N. N. Zein, “Pioglitazone improves early vireo logic kinetic response to PEG IFN/RBV combination therapy in hepatitis C genotype 1 naive pts,” Hepatology, vol. 48, article 383, 2008.

K. Overbeck, D. Genné, A. Golay, and F. Negro, “Pioglitazone in chronic hepatitis C not responding to pegylated interferon-α and ribavirin,” Journal of Hepatology, vol. 49, no. 2, pp. 295–298, 2008.

F. Negro, “Correction of insulin resistance in chronic hepatitis C patients not responding to the standard of care: more questions than answers,” Journal of Hepatology, vol. 50, no. 6, pp. 1271–1272, 2009.

K. H. Kim, H. J. Shin, K. Kim et al., “Hepatitis B Virus X Protein Induces Hepatic Steatosis Via Transcriptional Activation of SREBP1 and PPARγ,” Gastroenterology, vol. 132, no. 5, pp. 1955–1967, 2007.

L. G. Guidotti, C. M. Eggers, A. K. Raney et al., “In vivo regulation of hepatitis B virus replication by peroxisome proliferators,” Journal of Virology, vol. 73, no. 12, pp. 10377–10386, 1999.

Y. Waku, J. Inoue, Y. Ueno et al., “Inhibitory effect on hepatitis B virus in vitro by a peroxisome proliferator-activated receptor-β ligand, rosiglitazone,” Biochemical and Biophysical Research Communications, vol. 396, no. 2, pp. 508–514, 2010.

A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009.

G. Kristiansen, J. Jacob, A. C. Buckendahl et al., “Peroxisome proliferator-activated receptor γ is highly expressed in pancreatic cancer and is associated with shorter overall survival times,” Clinical Cancer Research, vol. 12, no. 21, pp. 6444–6451, 2006.

K. Hashimoto, B. J. Farrow, and B. M. Evers, “Activation and Role of MAP Kinases in 15d-PGJ2-Induced Apoptosis in the Human Pancreatic Cancer Cell Line Mia PaCa-2,” Pancreas, vol. 28, no. 2, pp. 153–159, 2004.

A. Galli, E. Ceni, D. W. Crabb et al., “Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms,” Gut, vol. 53, no. 11, pp. 1688–1697, 2004.

W. Motomura, M. Nagamine, S. Tanno et al., “Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells,” Journal of Gastroenterology, vol. 39, no. 5, pp. 461–468, 2004.
[85] G. Vitale, S. Zappavigna, M. Marra et al., “The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells,” Biotechnology Advances, vol. 30, no. 1, pp. 169–184, 2012.

[86] H. Koga, K. Selvendiran, R. Sivakumar et al., “PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells,” International Journal of Oncology, vol. 40, no. 3, pp. 679–685, 2012.

[87] P. Shah and S. Mudaliar, “Pioglitazone: side effect and safety profile,” Expert Opinion on Drug Safety, vol. 9, no. 2, pp. 347–354, 2010.

[88] C. V. Rizos, M. S. Elisa, D. P. Mikhailidis, and E. N. Liberopoulos, “How safe is the use of thiazolidinediones in clinical practice?” Expert Opinion on Drug Safety, vol. 8, no. 1, pp. 15–32, 2009.